WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/027903    International Application No.:    PCT/US2009/055190
Publication Date: 11.03.2010 International Filing Date: 27.08.2009
G01N 33/574 (2006.01), C07K 16/32 (2006.01), G01N 33/68 (2006.01)
Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER [US/US]; 1100 Fairview Avenue North, J5-110 Seattle, WA 98109 (US) (For All Designated States Except US).
HANASH, Samir, M. [US/US]; (US) (For US Only)
Inventors: HANASH, Samir, M.; (US)
Agent: ROSENMAN, Stephen, J.; Seed Intellectual Property Law Group PLLC Suite 5400 701 Fifth Avenue Seattle, WA 98104-7064 (US)
Priority Data:
61/095,269 08.09.2008 US
Abstract: front page image
(EN)Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and/or 14-3-3- theta and/or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated.
(FR)L'invention concerne le diagnostic du cancer du poumon chez un sujet avant l'apparition des symptômes (i.e., chez un sujet de pré-diagnostic) par dépistage, dans un fluide biologique provenant du sujet, de la présence d'auto-anticorps spécifiques pour une ou plusieurs protéines de pré-diagnotic indicatrices de cancer du poumon, notamment LAMR1, et notamment facultativement, de manière additionnelle ou alternative, annexine 1 et/ou protéines de pré-diagnostic du cancer du poumon thêta 14-3-3 et/ou autres ainsi qu'ici décrites en tant qu'antigènes définis. L'invention concerne également des procédés associés, notamment de surveillance de la réponse immunitaire face aux protéines indicatrices de cancer du poumon chez un patient atteint d'un cancer du poumon, de typage des sujets atteints de cancer du poumon ou de caractérisation des tumeurs pulmonaires, et d'application de l'approche protéomique ici décrite pour l'identification de protéines de pré-diagnostic indicatrices de cancer du poumon supplémentaires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)